Pfizer

Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy

Pfizer axes development of Duchenne muscular dystrophy antibody

https://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/

News/ News/ Pfizer/ R&D

Pfizer drug reduces mortality in patients with fatal heart disease

Joy Persaud cardiology, Pfizer, tafamidis 0 Comment

Pfizer’s heart disease drug, tafamidis, reduces mortality rates in patients, according to the top-line results of a phase

Pfizer drug reduces mortality in patients with fatal heart disease

https://pharmaphorum.com/news/tafamidis-reduces-mortality/

Iraq Flag 3D Rendering on Blue Sky Building Background

AstraZeneca/ News/ Pfizer/ Roche

Drug firms fight US government’s Iraq corruption probe

Joy Persaud litigation 0 Comment

US Department of Justice investigating J&J, Pfizer, Roche and others

Drug firms fight US government’s Iraq corruption probe

https://pharmaphorum.com/news/drug-firms-fight-us-governments-iraq-corruption-probe/

News/ Pfizer

US government may cease prescription rebates

Joy Persaud Pfizer, US drug prices 0 Comment

Pfizer’s CEO believes the US government will eliminate rebates on prescription drugs. As the company’s second quarter results

US government may cease prescription rebates

https://pharmaphorum.com/news/pfizers-ceo-believes-us-government-will-eliminate-prescription-rebates/

News/ Pfizer/ R&D/ US

Pfizer/Lilly non-opioid pain drug hits mark in phase 3 trial

Richard Staines Eli Lilly, neurology, pain, Pfizer 0 Comment

After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain drug is edging closer to approval, after

Pfizer/Lilly non-opioid pain drug hits mark in phase 3 trial

https://pharmaphorum.com/news/pfizer-lilly-tanezumab-pain-drug-hits-mark-in-phase-3-trial/

Bristol-Myers Squibb/ Market Access/ News/ News/ News/ Novo Nordisk/ Patients/ Pfizer/ Roche/ Top stories

Pfizer backed off, but the price hike game continues

Piotr Wnuk cancer, Diabetes, Donald Trump, pricing 0 Comment

Donald Trump may have convinced the US pharma giant Pfizer to defer a price increase for dozens of

Pfizer backed off, but the price hike game continues

https://pharmaphorum.com/news/pfizer-backed-off-but-the-price-hike-game-continues/

M&A/ News/ News/ Pfizer/ Sales and Marketing

Pfizer splits into three after failing to sell consumer unit

Richard Staines consumer health, M&A, Pfizer 0 Comment

Pfizer has decided to split into three after it failed to sell its consumer healthcare business a few

Pfizer splits into three after failing to sell consumer unit

https://pharmaphorum.com/news/pfizer-splits-into-three-after-failing-to-sell-consumer-unit/

Market Access/ News/ News/ News/ Patients/ Pfizer/ Top pharmaceutical companies

Pfizer defers drug price hike after Trump phone call

Piotr Wnuk Donald Trump, Pfizer, President Trump, Trump 0 Comment

Pfizer has decided to defer the recent drug price increase after a long discussion with president Trump and

Pfizer defers drug price hike after Trump phone call

https://pharmaphorum.com/news/pfizer-defers-drug-price-hike-after-trump-phone-call/

News/ Pfizer/ Top pharmaceutical companies/ Top stories

Pfizer increases prices in the US for the second time this year

Piotr Wnuk Donald Trump, Pfizer, pricing 0 Comment

The largest standalone drug maker in the US, announced it increase the prices of around 100 drugs for

Pfizer increases prices in the US for the second time this year

https://pharmaphorum.com/news/pfizer-increases-prices-us-second-time/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Pfizer

Login